Research institution
Centre Hospitalier St Anne Clinical Trials
Studies where Centre Hospitalier St Anne is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 42Primary Angiitis of the Central Nervous System (PACNS) in Remission
Efficacy of Rituximab for Remission Maintenance in Patients With Primary Angiitis of the Central Nervous System: an Open-label, Randomized, Controlled Trial Comparing Systematic Rituximab Infusions and Azathioprine
MAINRIPAC is a multicenter, randomized, open-label controlled clinical trial evaluating the efficacy of rituximab versus azathioprine for maintenance of remission in patients with primary angiitis of the central nervous system…
- Trial name
- MAINRIPAC (NCT07902492)
- Testing
- RUXIENCE®., Brain MRI, Azathioprine 50 MG
- Volunteers
- 74 people
- Sponsor
- Centre Hospitalier St Anne
Major Depressive Episode (MDE), Unipolar Disorder
Evaluating the Therapeutic Potential of Focal Electrically Administered Seizure Therapy (FEAST) in the Treatment of Depression: A Multicenter Randomized Clinical Trial
A significant proportion of patients remain resistant to antidepressant therapies, even when treatment is well managed. Electroconvulsive therapy (ECT) is a well-established method for treating certain severe and resistant…
- Conditions
- Major Depressive Episode (MDE), Unipolar Disorder, Bipolar 1 Disorder
- Trial name
- FEAST-AFT (NCT07857122)
- Testing
- Stimulation by the Sigma ECT/FEAST device, Stimulation by Sigmastim ECT 200J device administered in right unilateral (RUL), Stimulation by Sigmastim ECT 200J device administered in bilateral (BT)
- Where
- 5 sites in France, Monaco
- Volunteers
- 108 people
- Sponsor
- Centre Hospitalier St Anne
Mental Health
Study of Individual Neurocognitive Changes Associated With the Training of the Working Memory.
8 participants including 2 pilots. The 2 pilot participants will each execute an MRI acquisition session in order to adjust the experimental paradigm
- Trial name
- SAMPLEX (NCT07851051)
- Where
- France
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier St Anne
Schizophrenia, Treatment Resistant Depression (TRD)
Treatment Resistance in Psychiatric Disorders: the Search for Biological Markers Predictive of Response to Treatment
The disruption of immune system is a key candidate in the pathogenesis of psychiatric disorders, especially those resistant to traditional treatments.
- Conditions
- Schizophrenia, Treatment Resistant Depression (TRD), Bipolar Disorder (BD), Catatonia
- Trial name
- BIO-INM (NCT07741981)
- Testing
- Blood sampling, lumbar puncture, stool sampling, skin microbiopsy and psychometrics scales
- Where
- France
- Volunteers
- 700 people
- Sponsor
- Centre Hospitalier St Anne
Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD)
Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)
Psilocybin, a serotonin receptor agonist in the brain, significantly and quickly improves depressive symptoms while inducing profound acute subjective effects.
- Trial name
- PSILOTRAZ (NCT07210112)
- Testing
- Psilocybin 25 mg per os, Trazodone 5mg, Trazodone 30 mg
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Centre Hospitalier St Anne
Depression, Bipolar Disorder
Neuro-computational Study of Thymic Fluctuations in Mood Disorders
Depression and bipolar disorder are frequent, debilitating conditions. Both are thought to be primarily caused by an impaired regulation of mood, which is why they are sometimes referred to as "mood disorders".
- Conditions
- Depression, Bipolar Disorder, Recurrent Depression, Mood Disorders
- Trial name
- MOODELING (NCT07033923)
- Testing
- Brain magnetic resonance imaging (MRI) with structural (anatomical) and functional sequences (optional), Computerized cognitive tests, Daily longitudinal monitoring by mobile MOODELING application
- Where
- 2 sites in France
- Volunteers
- 588 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier St Anne
Treatment Resistant Schizophrenia
Reduction of Auditory-Verbal Hallucinations in Schizophrenia Through Cortical Neuromodulation
Approximately 1% of the general population will be affected by schizophrenia over the course of their lives, with life expectancy being reduced by 20 years on average and quality of life being severely diminished in affected…
- Trial name
- HALLUSTIM (NCT06361160)
- Testing
- Active Transcranial Magnetic Stimulation (TMS)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier St Anne
Schizophrenia
Voice-Based Biomarkers: A Novel Approach to Monitoring and Predicting Schizophrenia Relapses
Schizophrenia is a serious psychiatric illness affecting approximately 25 million people worldwide. Patients with schizophrenia experience hallucinations, auditory illusions, disordered thinking, movement disorders, cognitive…
- Trial name
- OBSERVSPEECH (NCT06613334)
- Testing
- Blood test: measurement of plasma antipsychotic concentration, Voice interviews and questionnaires carried out via the CALLYOPE application
- Where
- 2 sites in France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier St Anne
Pathology Requiring Deep Brain Stimulation Therapy
Determination of Biomarkers of the Effectiveness of Deep Brain Stimulation by Direct Electrophysiological Recordings of Brain Activity in a Cognitive Context - LFP-DBS 2024
Deep brain stimulation (DBS) is a therapeutic approach aimed at applying high-frequency, low-intensity electrical stimulation using electrodes implanted in subcortical structures and connected subcutaneously to a stimulator…
- Trial name
- LFP-DBS 2024 (NCT06813300)
- Testing
- Electrophysiological recordings
- Where
- 2 sites in France
- Volunteers
- 250 people
- Sponsor
- Centre Hospitalier St Anne
Typical Development, Typically Developing Children Ages 3 to 6
Assessment of Language Comprehension and Learning in Children Attending Child Psychiatry Services (TICOALA-SOINS)
Language is central to children's cognitive, emotional, and social development, and language difficulties are a frequent reason for consultation in child psychiatry, often co-occurring with psychiatric disorders.
- Conditions
- Typical Development, Typically Developing Children Ages 3 to 6, Typical Preschoolers Who Can Not Zipper, Children
- Trial name
- TICOALA-SOINS (NCT07283458)
- Testing
- TICOALA
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier St Anne